

File Copy

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 April 2001 (26.04.2001)

PCT

(10) International Publication Number
WO 01/29219 A1

(51) International Patent Classification⁷: C12N 15/12, C07K 14/47

(74) Agents: ISHIMOTO, Lance et al.; Lexicon Genetics Incorporated, 4000 Research Forest Drive, The Woodlands, TX 77381 (US).

(21) International Application Number: PCT/US00/28798

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 8 October 2000 (08.10.2000)

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/160,285 19 October 1999 (19.10.1999) US
60/183,583 18 February 2000 (18.02.2000) US

(71) Applicant: LEXICON GENETICS INCORPORATED [US/US]; 4000 Research Forest Drive, The Woodlands, TX 77381 (US).

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/29219 A1

(54) Title: HUMAN CUB-DOMAIN-CONTAINING PROTEIN AND GENE ENCODING THE SAME

(57) Abstract: A human protein containing a CUB-domain and its corresponding gene have been identified. The related polypeptidic and polynucleotidic sequences here disclosed can have therapeutic, diagnostic and pharmacogenomic applications.

HUMAN CUB-DOMAIN-CONTAINING PROTEIN AND GENE ENCODING THE SAME

The present invention claims the benefit of U.S.
5 Provisional Application Numbers 60/160,285 and 60/183,583
which were filed October 19, 1999 and February 18, 2000
respectively and are herein incorporated in their entirety.

1. INTRODUCTION

10 The present invention relates to the discovery,
identification, and characterization of novel human
polynucleotides encoding proteins sharing sequence similarity
with mammalian proteins having CUB domains. The invention
encompasses the described polynucleotides, host cell
15 expression systems, the encoded proteins, fusion proteins,
polypeptides and peptides, antibodies to the encoded proteins
and peptides, and genetically engineered animals that either
lack or over express the disclosed sequences, antagonists and
agonists of the proteins, and other compounds that modulate
20 the expression or activity of the proteins encoded by the
disclosed polynucleotides that can be used for diagnosis, drug
screening, clinical trial monitoring, or the treatment of
physiological disorders, or diseases.

25 2. BACKGROUND OF THE INVENTION

The CUB domain is an extracellular domain (ECD) present
in variety of diverse proteins such as bone morphogenetic
protein 1, proteinases, spemadhesins, complement
subcomponents, and neuronal recognition molecules. Given the
30 importance of these functions, CUB proteins have been
associated with, *inter alia*, regulating development,
modulating cellular processes, and preventing infectious
disease.

35 3. SUMMARY OF THE INVENTION

The present invention relates to the discovery,
identification, and characterization of nucleotides that
encode novel human proteins, and the corresponding amino acid

sequences of these proteins. The novel human proteins (NHPs) described for the first time herein share structural similarity with animal CUB domain proteins, coagulation factors V and XIII, milk fat globule-EGF factor 8, 5 transcriptional repressor AE-binding protein-1, and neuropilins 1 and 2 (which, like the presently described protein, contain both CUB and discoidin domains).

The novel human nucleic acid (cDNA) sequences described herein, encode proteins/open reading frames (ORFs) of 487, 10 586, and 539 amino acids in length (see SEQ ID NOS: 2, 4, and 6 respectively).

The invention also encompasses agonists and antagonists of the described NHPs, including small molecules, large molecules, mutant NHPs, or portions thereof that compete with 15 native NHPs, NHP peptides, and antibodies, as well as nucleotide sequences that can be used to inhibit the expression of the described NHPs (e.g., antisense and ribozyme molecules, and gene or regulatory sequence replacement constructs) or to enhance the expression of the described NHPs 20 (e.g., expression constructs that place the described gene under the control of a strong promoter system), and transgenic animals that express a NHP transgene, or "knock-outs" (which can be conditional) that do not express a functional NHP. Several knockout ES cell lines have been produced that contain 25 a gene trap mutation in a murine ortholog/homolog of the disclosed NHPs.

Further, the present invention also relates to processes for identifying compounds that modulate, i.e., act as agonists or antagonists, of NHP expression and/or NHP activity that 30 utilize purified preparations of the described NHPs and/or NHP products, or cells expressing the same. Such compounds can be used as therapeutic agents for the treatment of any of a wide variety of symptoms associated with biological disorders or imbalances.

4. DESCRIPTION OF THE SEQUENCE LISTING AND FIGURES

The Sequence Listing provides the sequences of several NHP ORFs encoding the described NHP amino acid sequences. SEQ ID NO:7 describes a NHP ORF and flanking sequences.

5

5. DETAILED DESCRIPTION OF THE INVENTION

The NHPs described for the first time herein are novel proteins that are expressed in, *inter alia*, human cell lines, and human prostate, pituitary, fetal brain, brain, thymus, spleen, lymph node, trachea, kidney, fetal liver, thyroid, adrenal gland, salivary gland, stomach, small intestine, colon, muscle, heart, mammary gland, adipose, skin, esophagus, bladder, cervix, rectum, and testis cells.

The described sequences were compiled from gene trapped cDNAs, genomic sequence, and clones isolated from human brain, adipose, testis, and placenta cDNA libraries (Edge Biosystems, Gaithersburg, MD, and Clontech, Palo Alto, CA). The present invention encompasses the nucleotides presented in the Sequence Listing, host cells expressing such nucleotides, the expression products of such nucleotides, and: (a) nucleotides that encode mammalian homologs of the described genes, including the specifically described NHPs, and NHP products; (b) nucleotides that encode one or more portions of a NHP that correspond to functional domains, and the polypeptide products specified by such nucleotide sequences, including but not limited to the novel regions of any active domain(s); (c) isolated nucleotides that encode mutant versions, engineered or naturally occurring, of the described NHPs in which all or a part of at least one domain is deleted or altered, and the polypeptide products specified by such nucleotide sequences, including but not limited to soluble proteins and peptides in which all or a portion of the signal sequence is deleted; (d) nucleotides that encode chimeric fusion proteins containing all or a portion of a coding region of a NHP, or one of its domains (e.g., a receptor or ligand binding domain, accessory protein/self-association domain, etc.) fused to another peptide or polypeptide; or (e) therapeutic or diagnostic

derivatives of the described polynucleotides such as oligonucleotides, antisense polynucleotides, ribozymes, dsRNA, or gene therapy constructs comprising a sequence first disclosed in the Sequence Listing.

- 5 As discussed above, the present invention includes:
- (a) the human DNA sequences presented in the Sequence Listing (and vectors comprising the same) and additionally contemplates any nucleotide sequence encoding a contiguous NHP open reading frame (ORF), or a contiguous exon splice junction
- 10 15 first described in the Sequence Listing, that hybridizes to a complement of a DNA sequence presented in the Sequence Listing under highly stringent conditions, e.g., hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65°C, and washing in 0.1xSSC/0.1% SDS at 68°C (Ausubel F.M. et al., eds., 1989, Current Protocols in Molecular Biology, Vol. I, Green Publishing Associates, Inc., and John Wiley & sons, Inc., New York, at p. 2.10.3) and encodes a functionally equivalent gene product. Additionally contemplated are any nucleotide sequences that hybridize to
- 20 25 the complement of the DNA sequence that encode and express an amino acid sequence presented in the Sequence Listing under moderately stringent conditions, e.g., washing in 0.2xSSC/0.1% SDS at 42°C (Ausubel et al., 1989, *supra*), yet still encode a functionally equivalent NHP product. Functional equivalents of a NHP include naturally occurring NHPs present in other species and mutant NHPs whether naturally occurring or engineered (by site directed mutagenesis, gene shuffling, directed evolution as described in, for example, U.S. Patent No. 5,837,458). The invention also includes degenerate
- 30 nucleic acid variants of the disclosed NHP polynucleotide sequences.

Additionally contemplated are polynucleotides encoding a NHP ORF, or its functional equivalent, encoded by a polynucleotide sequence that is about 99, 95, 90, or about 85 percent similar or identical to corresponding regions of the nucleotide sequences of the Sequence Listing (as measured by

BLAST sequence comparison analysis using, for example, the GCG sequence analysis package using standard default settings).

The invention also includes nucleic acid molecules, preferably DNA molecules, that hybridize to, and are therefore 5 the complements of, the described NHP gene nucleotide sequences. Such hybridization conditions may be highly stringent or less highly stringent, as described above. In instances where the nucleic acid molecules are deoxyoligonucleotides ("DNA oligos"), such molecules are 10 generally about 16 to about 100 bases long, or about 20 to about 80, or about 34 to about 45 bases long, or any variation or combination of sizes represented therein that incorporate a contiguous region of sequence first disclosed in the Sequence Listing. Such oligonucleotides can be used in conjunction 15 with the polymerase chain reaction (PCR) to screen libraries, isolate clones, and prepare cloning and sequencing templates, etc.

Alternatively, such NHP oligonucleotides can be used as hybridization probes for screening libraries, and assessing 20 gene expression patterns (particularly using a micro array or high-throughput "chip" format). Additionally, a series of the described NHP oligonucleotide sequences, or the complements thereof, can be used to represent all or a portion of the described NHP sequences. The oligonucleotides, typically 25 between about 16 to about 40 (or any whole number within the stated range) nucleotides in length may partially overlap each other and/or a NHP sequence may be represented using oligonucleotides that do not overlap. Accordingly, the described NHP polynucleotide sequences shall typically 30 comprise at least about two or three distinct oligonucleotide sequences of at least about 18, and preferably about 25, nucleotides in length that are each first disclosed in the described Sequence Listing. Such oligonucleotide sequences may begin at any nucleotide present within a sequence in the 35 Sequence Listing and proceed in either a sense (5'-to-3') orientation vis-a-vis the described sequence or in an antisense orientation.

For oligonucleotide probes, highly stringent conditions may refer, e.g., to washing in 6xSSC/0.05% sodium pyrophosphate at 37°C (for 14-base oligos), 48°C (for 17-base oligos), 55°C (for 20-base oligos), and 60°C (for 23-base 5 oligos). These nucleic acid molecules may encode or act as NHP gene antisense molecules, useful, for example, in NHP gene regulation (for and/or as antisense primers in amplification reactions of NHP gene nucleic acid sequences). With respect to NHP gene regulation, such techniques can be used to 10 regulate biological functions. Further, such sequences may be used as part of ribozyme and/or triple helix sequences that are also useful for NHP gene regulation.

Inhibitory antisense or double stranded oligonucleotides can additionally comprise at least one modified base moiety 15 which is selected from the group including but not limited to 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, 20 dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 25 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 30 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

The antisense oligonucleotide can also comprise at least one modified sugar moiety selected from the group including 35 but not limited to arabinose, 2-fluoroarabinose, xylulose, and hexose..

In yet another embodiment, the antisense oligonucleotide will comprise at least one modified phosphate backbone selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, 5 a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

In yet another embodiment, the antisense oligonucleotide is an α -anomeric oligonucleotide. An α -anomeric oligonucleotide forms specific double-stranded hybrids with 10 complementary RNA in which, contrary to the usual β -units, the strands run parallel to each other (Gautier et al., 1987, Nucl. Acids Res. 15:6625-6641). The oligonucleotide is a 2'-0-methylribonucleotide (Inoue et al., 1987, Nucl. Acids Res. 15:6131-6148), or a chimeric RNA-DNA analogue (Inoue et 15 al., 1987, FEBS Lett. 215:327-330). Alternatively, double stranded RNA can be used to disrupt the expression and function of a targeted NHP.

Oligonucleotides of the invention can be synthesized by standard methods known in the art, e.g. by use of an automated 20 DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides can be synthesized by the method of Stein et al. (1988, Nucl. Acids Res. 16:3209), and methylphosphonate oligonucleotides can be prepared by use of 25 controlled pore glass polymer supports (Sarin et al., 1988, Proc. Natl. Acad. Sci. U.S.A. 85:7448-7451), etc.

Low stringency conditions are well known to those of skill in the art, and will vary predictably depending on the specific organisms from which the library and the labeled 30 sequences are derived. For guidance regarding such conditions see, for example, Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual (and periodic updates thereof), Cold Springs Harbor Press, N.Y.; and Ausubel et al., 1989, Current Protocols in Molecular Biology, Green Publishing Associates 35 and Wiley Interscience, N.Y.

Alternatively, suitably labeled NHP nucleotide probes can be used to screen a human genomic library using appropriately

stringent conditions or by PCR. The identification and characterization of human genomic clones is helpful for identifying polymorphisms (including, but not limited to, nucleotide repeats, microsatellite alleles, single nucleotide polymorphisms, or coding single nucleotide polymorphisms), determining the genomic structure of a given locus/allele, and designing diagnostic tests. For example, sequences derived from regions adjacent to the intron/exon boundaries of the human gene can be used to design primers for use in amplification assays to detect mutations within the exons, introns, splice sites (e.g., splice acceptor and/or donor sites), etc., that can be used in diagnostics and pharmacogenomics.

Further, a NHP homolog can be isolated from nucleic acid from an organism of interest by performing PCR using two degenerate or "wobble" oligonucleotide primer pools designed on the basis of amino acid sequences within the NHP products disclosed herein. The template for the reaction may be total RNA, mRNA, and/or cDNA obtained by reverse transcription of mRNA prepared from human or non-human cell lines or tissue known or suspected to express an allele of a NHP gene. The PCR product can be subcloned and sequenced to ensure that the amplified sequences represent the sequence of the desired NHP gene. The PCR fragment can then be used to isolate a full length cDNA clone by a variety of methods. For example, the amplified fragment can be labeled and used to screen a cDNA library, such as a bacteriophage cDNA library. Alternatively, the labeled fragment can be used to isolate genomic clones via the screening of a genomic library.

PCR technology can also be used to isolate full length cDNA sequences. For example, RNA can be isolated, following standard procedures, from an appropriate cellular or tissue source (i.e., one known, or suspected, to express a NHP gene, such as, for example, testis tissue). A reverse transcription (RT) reaction can be performed on the RNA using an oligonucleotide primer specific for the most 5' end of the amplified fragment for the priming of first strand synthesis.

The resulting RNA/DNA hybrid may then be "tailed" using a standard terminal transferase reaction, the hybrid may be digested with RNase H, and second strand synthesis may then be primed with a complementary primer. Thus, cDNA sequences 5 upstream of the amplified fragment can be isolated. For a review of cloning strategies that can be used, see e.g., Sambrook et al., 1989, *supra*.

A cDNA encoding a mutant NHP gene can be isolated, for example, by using PCR. In this case, the first cDNA strand 10 may be synthesized by hybridizing an oligo-dT oligonucleotide to mRNA isolated from tissue known or suspected to be expressed in an individual putatively carrying a mutant NHP allele, and by extending the new strand with reverse transcriptase. The second strand of the cDNA is then 15 synthesized using an oligonucleotide that hybridizes specifically to the 5' end of the normal gene. Using these two primers, the product is then amplified via PCR, optionally cloned into a suitable vector, and subjected to DNA sequence analysis through methods well known to those of skill in the 20 art. By comparing the DNA sequence of the mutant NHP allele to that of a corresponding normal NHP allele, the mutation(s) responsible for the loss or alteration of function of the mutant NHP gene product can be ascertained.

Alternatively, a genomic library can be constructed using 25 DNA obtained from an individual suspected of or known to carry a mutant NHP allele (e.g., a person manifesting a NHP-associated phenotype such as, for example, obesity, high blood pressure, connective tissue disorders, infertility, etc.), or a cDNA library can be constructed using RNA from a tissue 30 known, or suspected, to express a mutant NHP allele. A normal NHP gene, or any suitable fragment thereof, can then be labeled and used as a probe to identify the corresponding mutant NHP allele in such libraries. Clones containing mutant NHP gene sequences can then be purified and subjected to 35 sequence analysis according to methods well known to those skilled in the art.

Additionally, an expression library can be constructed utilizing cDNA synthesized from, for example, RNA isolated from a tissue known, or suspected, to express a mutant NHP allele in an individual suspected of or known to carry such a 5 mutant allele. In this manner, gene products made by the putatively mutant tissue can be expressed and screened using standard antibody screening techniques in conjunction with antibodies raised against normal NHP product, as described below. (For screening techniques, see, for example, Harlow, 10 E. and Lane, eds., 1988, "Antibodies: A Laboratory Manual", Cold Spring Harbor Press, Cold Spring Harbor.)

Additionally, screening can be accomplished by screening with labeled NHP fusion proteins, such as, for example, alkaline phosphatase-NHP or NHP-alkaline phosphatase fusion proteins.

15 In cases where a NHP mutation results in an expressed gene product with altered function (e.g., as a result of a missense or a frameshift mutation), polyclonal antibodies to NHP are likely to cross-react with a corresponding mutant NHP gene product. Library clones detected via their reaction with such 20 labeled antibodies can be purified and subjected to sequence analysis according to methods well known in the art.

The invention also encompasses (a) DNA vectors that contain any of the foregoing NHP coding sequences and/or their complements (i.e., antisense); (b) DNA expression vectors that 25 contain any of the foregoing NHP coding sequences operatively associated with a regulatory element that directs the expression of the coding sequences (for example, baculo virus as described in U.S. Patent No. 5,869,336 herein incorporated by reference); (c) genetically engineered host cells that 30 contain any of the foregoing NHP coding sequences operatively associated with a regulatory element that directs the expression of the coding sequences in the host cell; and (d) genetically engineered host cells that express an endogenous NHP gene under the control of an exogenously introduced 35 regulatory element (i.e., gene activation). As used herein, regulatory elements include, but are not limited to, inducible and non-inducible promoters, enhancers, operators and other

elements known to those skilled in the art that drive and regulate expression. Such regulatory elements include but are not limited to the human cytomegalovirus (hCMV) immediate early gene, regulatable, viral elements (particularly retroviral LTR promoters), the early or late promoters of SV40 adenovirus, the lac system, the trp system, the TAC system, the TRC system, the major operator and promoter regions of phage lambda, the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase (PGK), the promoters of acid phosphatase, and the promoters of the yeast α -mating factors.

The present invention also encompasses antibodies and anti-idiotypic antibodies (including Fab fragments), antagonists and agonists of a NHP, as well as compounds or nucleotide constructs that inhibit expression of a NHP gene (transcription factor inhibitors, antisense and ribozyme molecules, or gene or regulatory sequence replacement constructs), or promote the expression of a NHP (e.g., expression constructs in which NHP coding sequences are operatively associated with expression control elements such as promoters, promoter/enancers, etc.).

The NHPs or NHP peptides, NHP fusion proteins, NHP nucleotide sequences, antibodies, antagonists and agonists can be useful for the detection of mutant NHPs or inappropriately expressed NHPs for the diagnosis of disease. The NHPs or NHP peptides, NHP fusion proteins, NHP nucleotide sequences, host cell expression systems, antibodies, antagonists, agonists and genetically engineered cells and animals can be used for screening for drugs (or high throughput screening of combinatorial libraries) effective in the treatment of the symptomatic or phenotypic manifestations of perturbing the normal function of NHP in the body. The use of engineered host cells and/or animals may offer an advantage in that such systems allow not only for the identification of compounds that bind to the endogenous receptor for a NHP, but can also identify compounds that trigger NHP-mediated activities or pathways.

Finally, the NHP products can be used as therapeutics. For example, soluble derivatives such as NHP peptides/domains corresponding to NHP, NHP fusion protein products (especially NHP-Ig fusion proteins, i.e., fusions of a NHP, or a domain of 5 a NHP, to an IgFc), NHP antibodies and anti-idiotypic antibodies (including Fab fragments), antagonists or agonists (including compounds that modulate or act on downstream targets in a NHP-mediated pathway) can be used to directly treat diseases or disorders. For instance, the administration 10 of an effective amount of soluble NHP, or a NHP-IgFc fusion protein or an anti-idiotypic antibody (or its Fab) that mimics a NHP could activate or effectively antagonize the endogenous NHP receptor. Nucleotide constructs encoding such NHP products can be used to genetically engineer host cells to 15 express such products *in vivo*; these genetically engineered cells function as "bioreactors" in the body delivering a continuous supply of a NHP, a NHP peptide, or a NHP fusion protein to the body. Nucleotide constructs encoding functional NHP, mutant NHPs, as well as antisense and ribozyme 20 molecules can also be used in "gene therapy" approaches for the modulation of NHP expression. Thus, the invention also encompasses pharmaceutical formulations and methods for treating biological disorders.

Various aspects of the invention are described in greater 25 detail in the subsections below.

5.1 THE NHP SEQUENCES

The cDNA sequences and corresponding deduced amino acid sequences of the described NHPs are presented in the Sequence 30 Listing. SEQ ID NO:7 describes a NHP ORF as well as flanking regions. The NHP nucleotides were obtained from human cDNA regions using probes and/or primers generated from human gene trapped sequence tags, and genomic sequence. Expression analysis has provided evidence that the described NHP can be 35 expressed a variety of human cells as well as gene trapped human cells.

5.2 NHPS AND NHP POLYPEPTIDES

NHPS, polypeptides, peptide fragments, mutated, truncated, or deleted forms of the NHPS, and/or NHP fusion proteins can be prepared for a variety of uses. These uses
5 include, but are not limited to, the generation of antibodies, as reagents in diagnostic assays, for the identification of other cellular gene products related to a NHP, as reagents in assays for screening for compounds that can be as pharmaceutical reagents useful in the therapeutic treatment of
10 mental, biological, or medical disorders and disease.

The Sequence Listing discloses the amino acid sequences encoded by the described NHP polynucleotides. The NHPS display an initiator methionines in DNA sequence contexts consistent with a translation initiation site, and several of
15 the ORFs display a consensus signal sequence which can indicate that the described NHP ORFs are secreted proteins, or can be membrane associated.

The NHP amino acid sequences of the invention include the amino acid sequences presented in the Sequence Listing as well
20 as analogues and derivatives thereof. Further, corresponding NHP homologues from other species are encompassed by the invention. In fact, any NHPS encoded by a NHP nucleotide sequence described above are within the scope of the invention, as are any novel polynucleotide sequences encoding
25 all or any novel portion of an amino acid sequence presented in the Sequence Listing. The degenerate nature of the genetic code is well known, and, accordingly, each amino acid presented in the Sequence Listing, is generically representative of the well known nucleic acid "triplet" codon,
30 or in many cases codons, that can encode the amino acid. As such, as contemplated herein, the amino acid sequences presented in the Sequence Listing, when taken together with the genetic code (see, for example, Table 4-1 at page 109 of "Molecular Cell Biology", 1986, J. Darnell et al. eds.,
35 Scientific American Books, New York, NY, herein incorporated by reference) are generically representative of all the

various permutations and combinations of nucleic acid sequences that can encode such amino acid sequences.

The invention also encompasses proteins that are functionally equivalent to the NHPs encoded by the presently described nucleotide sequences as judged by any of a number of criteria, including, but not limited to, the ability to bind and cleave a substrate of a NHP, or the ability to effect an identical or complementary downstream pathway, or a change in cellular metabolism (e.g., proteolytic activity, ion flux, tyrosine phosphorylation, etc.). Such functionally equivalent NHP proteins include, but are not limited to, additions or substitutions of amino acid residues within the amino acid sequence encoded by the NHP nucleotide sequences described above, but which result in a silent change, thus producing a functionally equivalent gene product. Amino acid substitutions can be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

A variety of host-expression vector systems can be used to express the NHP nucleotide sequences of the invention. Where, as in the present instance, a NHP peptide or NHP polypeptide is thought to be a soluble or secreted molecule, the peptide or polypeptide can be recovered from the culture media. Such expression systems also encompass engineered host cells that express NHP, or functional equivalent, *in situ*. Purification or enrichment of a NHP from such expression systems can be accomplished using appropriate detergents and lipid micelles and methods well known to those skilled in the art. However, such engineered host cells themselves may be used in situations where it is important not only to retain

the structural and functional characteristics of a NHP, but to assess biological activity, e.g., in drug screening assays.

The expression systems that may be used for purposes of the invention include but are not limited to microorganisms such as bacteria (e.g., *E. coli*, *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing NHP nucleotide sequences; yeast (e.g., *Saccharomyces*, *Pichia*) transformed with recombinant yeast expression vectors containing NHP encoding nucleotide sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing NHP sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing NHP nucleotide sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter).

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the NHP product being expressed. For example, when a large quantity of such a protein is to be produced for the generation of pharmaceutical compositions of and/or containing a NHP, or for raising antibodies to a NHP, vectors that direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the *E. coli* expression vector pUR278 (Ruther et al., 1983, EMBO J. 2:1791), in which a NHP coding sequence may be ligated individually into the vector in frame with the lacZ coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, 1985, Nucleic Acids Res. 13:3101-3109; Van Heeke & Schuster, 1989, J. Biol. Chem. 264:5503-5509); and the like. pGEX vectors (Pharmacia or American Type Culture Collection) can also be used to express

foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in
5 the presence of free glutathione. The PGEV vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

In an insect system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. A NHP coding sequence can be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for
15 example the polyhedrin promoter). Successful insertion of NHP coding sequence will result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (i.e., virus lacking the proteinaceous coat coded for by the polyhedrin gene). These recombinant viruses are then used to
20 infect *Spodoptera frugiperda* cells in which the inserted sequence is expressed (e.g., see Smith et al., 1983, J. Virol. 46: 584; Smith, U.S. Patent No. 4,215,051).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an
25 adenovirus is used as an expression vector, the NHP nucleotide sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or
30 in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing a NHP product in infected hosts (e.g., See Logan & Shenk, 1984, Proc. Natl. Acad. Sci. USA 81:3655-3659). Specific initiation
35 signals may also be required for efficient translation of inserted NHP nucleotide sequences. These signals include the ATG initiation codon and adjacent sequences. In cases where

an entire NHP sequence or cDNA, including its own initiation codon and adjacent sequences, is inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only a portion of a
5 NHP coding sequence is inserted, exogenous translational control signals, including, perhaps, the ATG initiation codon, must be provided. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous
10 translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (See Bittner et al., 1987, Methods in
15 Enzymol. 153:516-544).

In addition, a host cell strain may be chosen that modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and
20 processing (e.g., cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be
25 chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such
30 mammalian host cells include, but are not limited to, CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, WI38, and in particular, human cell lines.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell
35 lines which stably express the NHP sequences described above can be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be

transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign 5 DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form 10 foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express a NHP product. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that affect the endogenous activity of a NHP 15 product.

A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler, et al., 1977, Cell 11:223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, 1962, Proc. 20 Natl. Acad. Sci. USA 48:2026), and adenine phosphoribosyltransferase (Lowy, et al., 1980, Cell 22:817) genes can be employed in tk⁻, hprt⁻ or aprt⁻ cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which 25 confers resistance to methotrexate (Wigler, et al., 1980, Natl. Acad. Sci. USA 77:3567; O'Hare, et al., 1981, Proc. Natl. Acad. Sci. USA 78:1527); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, 1981, Proc. Natl. Acad. Sci. USA 78:2072); neo, which confers resistance to the 30 aminoglycoside G-418 (Colberre-Garapin, et al., 1981, J. Mol. Biol. 150:1); and hygro, which confers resistance to hygromycin (Santerre, et al., 1984, Gene 30:147).

Alternatively, any fusion protein can be readily purified by utilizing an antibody specific for the fusion protein being 35 expressed. For example, a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht, et al.,

1991, Proc. Natl. Acad. Sci. USA 88:8972-8976). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the gene's open reading frame is translationally fused to an amino-terminal tag consisting 5 of six histidine residues. Extracts from cells infected with recombinant vaccinia virus are loaded onto Ni²⁺-nitriloacetic acid-agarose columns and histidine-tagged proteins are selectively eluted with imidazole-containing buffers.

10 **5.3 ANTIBODIES TO NHP PRODUCTS**

Antibodies that specifically recognize one or more epitopes of a NHP, or epitopes of conserved variants of a NHP, or peptide fragments of a NHP are also encompassed by the invention. Such antibodies include but are not limited to 15 polyclonal antibodies, monoclonal antibodies (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab')₂ fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above.

20 The antibodies of the invention may be used, for example, in the detection of a NHP in a biological sample and may, therefore, be utilized as part of a diagnostic or prognostic technique whereby patients may be tested for abnormal amounts of NHP. Such antibodies may also be utilized in conjunction 25 with, for example, compound screening schemes for the evaluation of the effect of test compounds on expression and/or activity of a NHP sequence product. Additionally, such antibodies can be used in conjunction gene therapy to, for example, evaluate the normal and/or engineered NHP-expressing 30 cells prior to their introduction into the patient. Such antibodies may additionally be used as a method for the inhibition of abnormal NHP activity. Thus, such antibodies may, therefore, be utilized as part of treatment methods.

For the production of antibodies, various host animals 35 may be immunized by injection with a NHP, an NHP peptide (e.g., one corresponding to a functional domain of a NHP), truncated NHP polypeptides (NHP in which one or more domains

have been deleted), functional equivalents of a NHP or mutated variants of a NHP. Such host animals may include but are not limited to pigs, rabbits, mice, goats, and rats, to name but a few. Various adjuvants may be used to increase the
5 immunological response, depending on the host species, including but not limited to Freund's adjuvant (complete and incomplete), mineral salts such as aluminum hydroxide or aluminum phosphate, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil
10 emulsions, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and *Corynebacterium parvum*. Alternatively, the immune response could be enhanced by combination and or coupling with molecules such as keyhole limpet hemocyanin, tetanus toxoid, diphtheria toxoid,
15 ovalbumin, cholera toxin or fragments thereof. Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of the immunized animals.

Monoclonal antibodies, which are homogeneous populations of antibodies to a particular antigen, can be obtained by any
20 technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique of Kohler and Milstein, (1975, *Nature* 256:495-497; and U.S. Patent No. 4,376,110), the human B-cell hybridoma technique (Kosbor et
25 al., 1983, *Immunology Today* 4:72; Cole et al., 1983, *Proc. Natl. Acad. Sci. USA* 80:2026-2030), and the EBV-hybridoma technique (Cole et al., 1985, *Monoclonal Antibodies And Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96). Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA,
30 IgD and any subclass thereof. The hybridoma producing the mAb of this invention may be cultivated in vitro or in vivo. Production of high titers of mAbs in vivo makes this the presently preferred method of production.

In addition, techniques developed for the production of
35 "chimeric antibodies" (Morrison et al., 1984, *Proc. Natl. Acad. Sci.*, 81:6851-6855; Neuberger et al., 1984, *Nature*, 312:604-608; Takeda et al., 1985, *Nature*, 314:452-454) by

splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region. Such technologies are described in U.S. Patents Nos. 6,075,181 and 5,877,397 and their respective disclosures which are herein incorporated by reference in their entirety.

Alternatively, techniques described for the production of single chain antibodies (U.S. Patent 4,946,778; Bird, 1988, Science 242:423-426; Huston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; and Ward et al., 1989, Nature 334:544-546) can be adapted to produce single chain antibodies against NHP sequence products. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide.

Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, such fragments include, but are not limited to: the $F(ab')_2$ fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the $F(ab')_2$ fragments. Alternatively, Fab expression libraries may be constructed (Huse et al., 1989, Science, 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.

Antibodies to a NHP can, in turn, be utilized to generate anti-idiotype antibodies that "mimic" a given NHP, using techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, 1993, FASEB J 7(5):437-444; and Nissinoff, 1991, J. Immunol. 147(8):2429-2438). For example antibodies which bind to a NHP domain and competitively inhibit the binding of NHP to its cognate receptor can be used to generate anti-idiotypes that "mimic" a NHP and, therefore, bind and activate or neutralize a receptor. Such anti-

idiotypic antibodies or Fab fragments of such anti-idiotypes can be used in therapeutic regimens involving a NHP signaling pathway.

The present invention is not to be limited in scope by
5 the specific embodiments described herein, which are intended
as single illustrations of individual aspects of the
invention, and functionally equivalent methods and components
are within the scope of the invention. Indeed, various
10 modifications of the invention, in addition to those shown and
described herein will become apparent to those skilled in the
art from the foregoing description. Such modifications are
intended to fall within the scope of the appended claims. All
cited publications, patents, and patent applications are
herein incorporated by reference in their entirety.

WHAT IS CLAIMED IS:

1. An isolated nucleic acid molecule comprising at least 24 contiguous bases of nucleotide sequence first disclosed in the NHP sequence described in SEQ ID NO: 3.
2. An isolated nucleic acid molecule comprising a nucleotide sequence that:
 - (a) encodes the amino acid sequence shown in SEQ ID NO: 4; and
 - (b) hybridizes under stringent conditions to the nucleotide sequence of SEQ ID NO: 3 or the complement thereof.
3. An isolated nucleic acid molecule according to Claim 1 wherein said nucleotide sequence is present in cDNA.
4. An isolated nucleic acid molecule encoding the amino acid sequence presented in SEQ ID NO:2.
5. An isolated nucleic acid molecule encoding the amino acid sequence presented in SEQ ID NO:6.

SEQUENCE LISTING

<110> Donoho, Gregory
 Turner, C. Alexander Jr.
 Nehls, Michael
 Friedrich, Glenn
 Zambrowicz, Brian
 Sands, Arthur T.

<120> Novel Human Proteins and Polynucleotides
 Encoding the Same

<130> LEX-0071-PCT

<150> US 60/160,285
<151> 1999-10-19

<150> US 60/183,583
<151> 2000-02-18

<160> 7

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 1464
<212> DNA
<213> homo sapiens

<400> 1

atgacatcta	agaattatcc	cgggacctac	cccaatcaca	ctgtttgcga	aaagacaatt	60
acagtaccaa	agggaaaag	actgattctg	agggtggag	atttggatat	cgaatcccag	120
acctgtgctt	ctgactatct	tctcttcacc	agctcttcag	atcaatatgg	tccatactgt	180
ggaagtatga	ctgttcccaa	agaactcttg	ttgaacacaaa	gtgaagttaac	cgtccgcctt	240
gagagtggat	cccacattc	tggccgggt	tttttgcgt	cctatgcgag	cagcgaccat	300
ccagatttaa	taacatgtt	ggaacgagct	agccattatt	tgaagacaga	atacagcaaa	360
ttctgcccag	ctgttgttag	agacgttagc	ggagacattt	ctggaaatat	ggttagatgga	420
tatagagata	cctcttatt	gtgcaaaggt	gccatccatg	caggaataat	tgctgtatgaa	480
ctagttggcc	agatcagtgt	gcttcagcgc	aaaggatca	gtcgatgtat	agggattctg	540
gccaatgggt	ttcttcgag	ggatggttcc	ctgtcagaca	agcgatttct	gtttacctcc	600
aatggttgca	gcagatcctt	gagtttggaa	cctgacgggc	aaatcagagc	ttcttcctca	660
tggcagtccg	tcaatgagag	tggagaccaa	gttcaactgtt	cttcctggcca	agcccgactt	720
caggaccaag	gcccatcatg	ggcttcgggc	gacagtagca	acaaccacaa	accacgagag	780
tggctggaga	tcgatttggg	ggagaaaaag	aaaataacag	gaattaggac	cacaggatct	840
acacagtctg	acttcaactt	ttatgttaag	agttttgtga	tgaacttcaa	aaacaataat	900
tctaagtgg	agacctataa	aggaattgt	aataatgaa	aaaaggtgtt	tcagggtAAC	960
tctaactttc	gggacccagt	gcaaaaacaat	ttcatccctc	ccatcggtggc	cagatatgtg	1020
cgggttgtcc	cccacacatg	gcaccagagg	atagccttga	aggtggagct	cattgggtgc	1080
cagattacac	aaggtaatga	ttcattgttgc	tggcgaaga	caagtcaaag	caccagtgtt	1140
tcaactaaga	aagaagatga	gacaatcaca	aggcccatcc	cctcggaaaga	aacatccaca	1200
ggaataaaca	ttacaacgtt	ggcttattcca	ttgggtgtcc	ttgttgtcct	gggtttgt	1260
ggaatgggaa	tctttgcagc	ctttagaaaag	aagaagaaga	aaggaagtc	gtatggatca	1320
gcggagggtc	agaaaaacaga	ctgttggaaag	cagattaaat	atccctttgc	cagacatcag	1380
tcaagctgagt	ttaccatcag	ctatgataat	gagaaggaga	tgacacaaaa	gttagatctc	1440
atcacaagt	atatggcagg	ttaa				1464

<210> 2
<211> 487
<212> PRT
<213> homo sapiens

<400> 2

Met Thr Ser Lys Asn Tyr Pro Gly Thr Tyr Pro Asn His Thr Val Cys
 1 5 10 15
 Glu Lys Thr Ile Thr Val Pro Lys Gly Lys Arg Leu Ile Leu Arg Leu
 20 25 30
 Gly Asp Leu Asp Ile Glu Ser Gln Thr Cys Ala Ser Asp Tyr Leu Leu
 35 40 45
 Phe Thr Ser Ser Ser Asp Gln Tyr Gly Pro Tyr Cys Gly Ser Met Thr
 50 55 60
 Val Pro Lys Glu Leu Leu Asn Thr Ser Glu Val Thr Val Arg Phe
 65 70 75 80
 Glu Ser Gly Ser His Ile Ser Gly Arg Gly Phe Leu Leu Thr Tyr Ala
 85 90 95
 Ser Ser Asp His Pro Asp Leu Ile Thr Cys Leu Glu Arg Ala Ser His
 100 105 110
 Tyr Leu Lys Thr Glu Tyr Ser Lys Phe Cys Pro Ala Gly Cys Arg Asp
 115 120 125
 Val Ala Gly Asp Ile Ser Gly Asn Met Val Asp Gly Tyr Arg Asp Thr
 130 135 140
 Ser Leu Leu Cys Lys Ala Ala Ile His Ala Gly Ile Ile Ala Asp Glu
 145 150 155 160
 Leu Gly Gly Gln Ile Ser Val Leu Gln Arg Lys Gly Ile Ser Arg Tyr
 165 170 175
 Glu Gly Ile Leu Ala Asn Gly Val Leu Ser Arg Asp Gly Ser Leu Ser
 180 185 190
 Asp Lys Arg Phe Leu Phe Thr Ser Asn Gly Cys Ser Arg Ser Leu Ser
 195 200 205
 Phe Glu Pro Asp Gly Gln Ile Arg Ala Ser Ser Trp Gln Ser Val
 210 215 220
 Asn Glu Ser Gly Asp Gln Val His Trp Ser Pro Gly Gln Ala Arg Leu
 225 230 235 240
 Gln Asp Gln Gly Pro Ser Trp Ala Ser Gly Asp Ser Ser Asn Asn His
 245 250 255
 Lys Pro Arg Glu Trp Leu Glu Ile Asp Leu Gly Glu Lys Lys Lys Ile
 260 265 270
 Thr Gly Ile Arg Thr Thr Gly Ser Thr Gln Ser Asn Phe Asn Phe Tyr
 275 280 285
 Val Lys Ser Phe Val Met Asn Phe Lys Asn Asn Ser Lys Trp Lys
 290 295 300
 Thr Tyr Lys Gly Ile Val Asn Asn Glu Glu Lys Val Phe Gln Gly Asn
 305 310 315 320
 Ser Asn Phe Arg Asp Pro Val Gln Asn Asn Phe Ile Pro Pro Ile Val
 325 330 335
 Ala Arg Tyr Val Arg Val Val Pro Gln Thr Trp His Gln Arg Ile Ala
 340 345 350
 Leu Lys Val Glu Leu Ile Gly Cys Gln Ile Thr Gln Gly Asn Asp Ser
 355 360 365
 Leu Val Trp Arg Lys Thr Ser Gln Ser Thr Ser Val Ser Thr Lys Lys
 370 375 380
 Glu Asp Glu Thr Ile Thr Arg Pro Ile Pro Ser Glu Glu Thr Ser Thr
 385 390 395 400
 Gly Ile Asn Ile Thr Thr Val Ala Ile Pro Leu Val Leu Val Val
 405 410 415
 Leu Val Phe Ala Gly Met Gly Ile Phe Ala Ala Phe Arg Lys Lys Lys
 420 425 430
 Lys Lys Gly Ser Pro Tyr Gly Ser Ala Glu Ala Gln Lys Thr Asp Cys
 435 440 445
 Trp Lys Gln Ile Lys Tyr Pro Phe Ala Arg His Gln Ser Ala Glu Phe
 450 455 460
 Thr Ile Ser Tyr Asp Asn Glu Lys Glu Met Thr Gln Lys Leu Asp Leu
 465 470 475 480
 Ile Thr Ser Asp Met Ala Gly
 485

<210> 3
<211> 1761
<212> DNA
<213> homo sapiens

<400> 3

atgggattcg	gtgcggggca	gcgactgcgc	cccgtcccg	cgccgcgc	gtccgcagag	60
gaggcggccc	ggccggggca	gctgcggctc	gggatccgtc	gaggggaggc	cgagctgcc	120
aagctggcgc	ccagcggggt	catggtgc	cccgccccgg	gcggcggcgc	actggcgcgg	180
gctgcggg	ggggcctc	ggcttgc	ctcgccgtct	ccgccccgt	ccggctgcag	240
gcggaggagc	tgggtatgg	ctgtggacac	ctagtgcactt	atcaggatag	tggcacatg	300
acatctaaga	attatcccg	gacctacccc	aatcacactg	tttgcgaaaa	gacaattaca	360
gtaccaaagg	ggaaaagact	gattctgagg	ttgggagatt	tggatatcg	atcccagacc	420
tgtgcttc	actatcttct	cttcaccagc	tcttcagatc	aatatggtcc	atactgtgga	480
agtatgactg	ttcccaaaga	actcttgc	aacacaagtg	aagtaaccgt	ccgctttgag	540
agtggatccc	acatttctgg	ccgggg	ttgtgcacct	atgcgagcag	cgaccatcca	600
gatttaataa	catgttgg	acgagcttagc	cattattgt	agacagaata	cagcaaattc	660
tgccca	gtttagaga	cgtagcagga	gacattctg	ggaatattgt	agatggat	720
agagataac	cttattgt	caaagctg	atccatgcag	gataattgc	tgtgaacta	780
ggtggccaga	tcagtgtgc	tcagcg	gggatccgtc	gatatgaagg	gattctggc	840
aatgggtt	tttcgaggga	tggttcc	tcagacaagc	gatttctgtt	tacctcca	900
ggttg	cagca	gatcc	tttgaac	gacgggcaaa	tcagagctt	960
cagtcgg	tgc	tttgc	tttgc	ttc	ttc	1020
gaccaagg	ccat	ttc	ttc	ttc	ttc	1080
ctggagatc	at	ttt	ttt	ttt	ttt	1140
cagtcgaa	act	ttt	ttt	ttt	ttt	1200
aagtggaa	ctataa	agg	attgt	aat	gaa	1260
aacttcc	acc	actg	gt	gaa	gggt	1320
gttgc	cccc	gtc	tttgc	tttgc	tttgc	1380
attacaca	ag	acat	ggat	tttgc	tttgc	1440
actaagaa	aa	gat	tttgc	tttgc	tttgc	1500
ataaa	acat	tttgc	tttgc	tttgc	tttgc	1560
atggggat	ct	tttgc	tttgc	tttgc	tttgc	1620
gaggctc	aga	aa	aa	aa	aa	1680
gctgag	ttt	tttgc	tttgc	tttgc	tttgc	1740
acaagt	gtataat	tttgc	tttgc	tttgc	tttgc	1761

<210> 4
<211> 586
<212> PRT
<213> homo sapiens

<400> 4

Met	Gly	Phe	Gly	Ala	Gly	Gln	Arg	Leu	Arg	Pro	Val	Pro	Ala	Pro	Arg
1				5				10					15		
Ser	Ser	Ala	Glu	Glu	Ala	Ala	Arg	Pro	Gly	Gln	Leu	Arg	Leu	Gly	Ile
						20			25				30		
Arg	Arg	Gly	Glu	Ala	Glu	Leu	Ala	Lys	Leu	Ala	Pro	Ser	Gly	Val	Met
						35			40				45		
Val	Pro	Gly	Ala	Arg	Gly	Gly	Ala	Leu	Ala	Arg	Ala	Ala	Gly	Arg	
						50			55				60		
Gly	Leu	Leu	Ala	Leu	Leu	Ala	Val	Ser	Ala	Pro	Leu	Arg	Leu	Gln	
65						70			75				80		
Ala	Glu	Glu	Leu	Gly	Asp	Gly	Cys	Gly	His	Leu	Val	Thr	Tyr	Gln	Asp
						85			90				95		
Ser	Gly	Thr	Met	Thr	Ser	Lys	Asn	Tyr	Pro	Gly	Thr	Tyr	Pro	Asn	His
						100			105				110		
Thr	Val	Cys	Glu	Lys	Thr	Ile	Thr	Val	Pro	Lys	Gly	Lys	Arg	Leu	Ile
						115			120				125		
Leu	Arg	Leu	Gly	Asp	Leu	Asp	Ile	Glu	Ser	Gln	Thr	Cys	Ala	Ser	Asp
						130			135				140		
Tyr	Leu	Leu	Phe	Thr	Ser	Ser	Ser	Asp	Gln	Tyr	Gly	Pro	Tyr	Cys	Gly
145						150			155				160		

Ser Met Thr Val Pro Lys Glu Leu Leu Leu Asn Thr Ser Glu Val Thr
 165 170 175
 Val Arg Phe Glu Ser Gly Ser His Ile Ser Gly Arg Gly Phe Leu Leu
 180 185 190
 Thr Tyr Ala Ser Ser Asp His Pro Asp Leu Ile Thr Cys Leu Glu Arg
 195 200 205
 Ala Ser His Tyr Leu Lys Thr Glu Tyr Ser Lys Phe Cys Pro Ala Gly
 210 215 220
 Cys Arg Asp Val Ala Gly Asp Ile Ser Gly Asn Met Val Asp Gly Tyr
 225 230 235 240
 Arg Asp Thr Ser Leu Leu Cys Lys Ala Ala Ile His Ala Gly Ile Ile
 245 250 255
 Ala Asp Glu Leu Gly Gly Gln Ile Ser Val Leu Gln Arg Lys Gly Ile
 260 265 270
 Ser Arg Tyr Glu Gly Ile Leu Ala Asn Gly Val Leu Ser Arg Asp Gly
 275 280 285
 Ser Leu Ser Asp Lys Arg Phe Leu Phe Thr Ser Asn Gly Cys Ser Arg
 290 295 300
 Ser Leu Ser Phe Glu Pro Asp Gly Gln Ile Arg Ala Ser Ser Ser Trp
 305 310 315 320
 Gln Ser Val Asn Glu Ser Gly Asp Gln Val His Trp Ser Pro Gly Gln
 325 330 335
 Ala Arg Leu Gln Asp Gln Gly Pro Ser Trp Ala Ser Gly Asp Ser Ser
 340 345 350
 Asn Asn His Lys Pro Arg Glu Trp Leu Glu Ile Asp Leu Gly Glu Lys
 355 360 365
 Lys Lys Ile Thr Gly Ile Arg Thr Thr Gly Ser Thr Gln Ser Asn Phe
 370 375 380
 Asn Phe Tyr Val Lys Ser Phe Val Met Asn Phe Lys Asn Asn Asn Ser
 385 390 395 400
 Lys Trp Lys Thr Tyr Lys Gly Ile Val Asn Asn Glu Glu Lys Val Phe
 405 410 415
 Gln Gly Asn Ser Asn Phe Arg Asp Pro Val Gln Asn Asn Phe Ile Pro
 420 425 430
 Pro Ile Val Ala Arg Tyr Val Arg Val Val Pro Gln Thr Trp His Gln
 435 440 445
 Arg Ile Ala Leu Lys Val Glu Leu Ile Gly Cys Gln Ile Thr Gln Gly
 450 455 460
 Asn Asp Ser Leu Val Trp Arg Lys Thr Ser Gln Ser Thr Ser Val Ser
 465 470 475 480
 Thr Lys Lys Glu Asp Glu Thr Ile Thr Arg Pro Ile Pro Ser Glu Glu
 485 490 495
 Thr Ser Thr Gly Ile Asn Ile Thr Thr Val Ala Ile Pro Leu Val Leu
 500 505 510
 Leu Val Val Leu Val Phe Ala Gly Met Gly Ile Phe Ala Ala Phe Arg
 515 520 525
 Lys Lys Lys Lys Gly Ser Pro Tyr Gly Ser Ala Glu Ala Gln Lys
 530 535 540
 Thr Asp Cys Trp Lys Gln Ile Lys Tyr Pro Phe Ala Arg His Gln Ser
 545 550 555 560
 Ala Glu Phe Thr Ile Ser Tyr Asp Asn Glu Lys Glu Met Thr Gln Lys
 565 570 575
 Leu Asp Leu Ile Thr Ser Asp Met Ala Gly
 580 585

<210> 5

<211> 1620

<212> DNA

<213> homo sapiens

<400> 5

atgggtccccg gcccccgccgg cggccgcgcga ctggcgcgggg ctgccggggcg gggccttcctg
 gctttgtgc tcgcggtctc cgcccccgtc cggctgcagg cggaggagct gggtgatggc

60

120

tgtggacacc	tagtgactta	tcaggatagt	ggcacaatga	catctaagaa	ttatccggg	180
acctaccca	atcacactgt	ttgcgaaaag	acaattacag	taccaaaggg	gaaaagactg	240
attctgaggt	tggagagtt	ggatatcgaa	tcccagacct	gtgcttctga	ctatcttc	300
ttcaccagct	ttccagatca	atatggtcca	tactgtggaa	gtatgactgt	tcccaaagaa	360
ctcttggta	acacaagtga	agtaaccgtc	cgcttgaga	gtggatccca	catttctggc	420
cggggttt	tgctgaccta	tgcgagcagc	gaccatccag	attaataac	atgtttggaa	480
cgagctagcc	attatttggaa	gacagaatac	agcaaaattct	gcccagctgg	tttagagac	540
gtagcaggag	acatttctgg	gaatatggta	gatggatata	gagatacctc	tttattgtgc	600
aaagctgcca	tccatgcagg	aataattgtt	gatgaactag	gtggccatg	cagtgtgctt	660
cagcgcaaag	ggatcagtgc	atatgaaggg	attctggcca	atgtgttct	ttcgaggat	720
ggttccctgt	cagacaagcg	atttctgtt	acctccaatg	gttgcagcag	atccttgagt	780
tttgaacctg	acggcCAAAT	cagagcttc	tcctcatggc	agtcggtaa	tgagagtgg	840
gaccaagttc	actggctcc	tggccaagcc	cgacttcagg	accaaggccc	atcatggct	900
tcgggCGACA	gtagcaacaa	ccacaaacca	cgagagtggc	tggagatcga	tttgggggag	960
aaaaagaaaaa	taacaggaat	taggaccaca	ggatctacac	agtcgaactt	caacttttat	1020
gttaagagt	ttgtgatgaa	cttccaaaac	aataattcta	atgttggaaagac	ctataaagga	1080
attgtgaata	atgaagaaaa	ggtgtttcag	gttaactcta	actttcggga	cccagtgc当地	1140
aacaatttca	tcctccat	cgtggccaga	tatgtgcggg	ttgtccccca	gacatggcac	1200
cagaggatag	ccttgaaggt	ggagcttcatt	gggtgccaga	ttacacaagg	taatgattca	1260
ttggtgtggc	gcaagacaag	tcaaagcacc	agtgtttca	ctaagaaaaa	agatgagaca	1320
atcacaaggc	ccatccccctc	ggaagaaaaca	tccacaggaa	taaacattac	aacgggtggct	1380
atccatttg	tgctccttgc	tgtcctgggt	tttgcggaa	tggggatctt	tgagcctt	1440
agaaagaaaaa	agaagaaaagg	aagtccgtat	ggatcagcgg	aggctcagaa	aacagactgt	1500
tgaaagcaga	ttaaatatcc	ctttggccaga	catcagtcag	ctgagtttac	catcagctat	1560
gataatgaga	aggagatgac	acaaaagtta	gatctcatca	caagtgatat	ggcaggtta	1620

<210> 6

<211> 539

<212> PRT

<213> homo sapiens

<400> 6

Met	Val	Pro	Gly	Ala	Arg	Gly	Gly	Gly	Ala	Leu	Ala	Arg	Ala	Ala	Gly
1				5				10				15			
Arg	Gly	Leu	Leu	Ala	Leu	Leu	Leu	Ala	Val	Ser	Ala	Pro	Leu	Arg	Leu
					20				25				30		
Gln	Ala	Glu	Glu	Leu	Gly	Asp	Gly	Cys	Gly	His	Leu	Val	Thr	Tyr	Gln
					35			40				45			
Asp	Ser	Gly	Thr	Met	Thr	Ser	Lys	Asn	Tyr	Pro	Gly	Thr	Tyr	Pro	Asn
				50			55			60					
His	Thr	Val	Cys	Glu	Lys	Thr	Ile	Thr	Val	Pro	Lys	Gly	Lys	Arg	Leu
				65			70			75			80		
Ile	Leu	Arg	Leu	Gly	Asp	Leu	Asp	Ile	Glu	Ser	Gln	Thr	Cys	Ala	Ser
				85				90				95			
Asp	Tyr	Leu	Leu	Phe	Thr	Ser	Ser	Asp	Gln	Tyr	Gly	Pro	Tyr	Cys	
				100			105				110				
Gly	Ser	Met	Thr	Val	Pro	Lys	Glu	Leu	Leu	Leu	Asn	Thr	Ser	Glu	Val
				115			120				125				
Thr	Val	Arg	Phe	Glu	Ser	Gly	Ser	His	Ile	Ser	Gly	Arg	Gly	Phe	Leu
				130			135			140					
Leu	Thr	Tyr	Ala	Ser	Ser	Asp	His	Pro	Asp	Leu	Ile	Thr	Cys	Leu	Glu
				145			150			155			160		
Arg	Ala	Ser	His	Tyr	Leu	Lys	Thr	Glu	Tyr	Ser	Lys	Phe	Cys	Pro	Ala
				165			170			175					
Gly	Cys	Arg	Asp	Val	Ala	Gly	Asp	Ile	Ser	Gly	Asn	Met	Val	Asp	Gly
				180			185			190					
Tyr	Arg	Asp	Thr	Ser	Leu	Leu	Cys	Lys	Ala	Ala	Ile	His	Ala	Gly	Ile
				195			200			205					
Ile	Ala	Asp	Glu	Leu	Gly	Gly	Gln	Ile	Ser	Val	Leu	Gln	Arg	Lys	Gly
				210			215			220					
Ile	Ser	Arg	Tyr	Glu	Gly	Ile	Leu	Ala	Asn	Gly	Val	Leu	Ser	Arg	Asp
				225			230			235			240		
Gly	Ser	Leu	Ser	Asp	Lys	Arg	Phe	Leu	Phe	Thr	Ser	Asn	Gly	Cys	Ser

245	250	255
Arg Ser Leu Ser Phe Glu Pro Asp Gly Gln Ile Arg Ala Ser Ser Ser		
260	265	270
Trp Gln Ser Val Asn Glu Ser Gly Asp Gln Val His Trp Ser Pro Gly		
275	280	285
Gln Ala Arg Leu Gln Asp Gln Gly Pro Ser Trp Ala Ser Gly Asp Ser		
290	295	300
Ser Asn Asn His Lys Pro Arg Glu Trp Leu Glu Ile Asp Leu Gly Glu		
305	310	315
Lys Lys Lys Ile Thr Gly Ile Arg Thr Thr Gly Ser Thr Gln Ser Asn		
325	330	335
Phe Asn Phe Tyr Val Lys Ser Phe Val Met Asn Phe Lys Asn Asn Asn		
340	345	350
Ser Lys Trp Lys Thr Tyr Lys Gly Ile Val Asn Asn Glu Glu Lys Val		
355	360	365
Phe Gln Gly Asn Ser Asn Phe Arg Asp Pro Val Gln Asn Asn Phe Ile		
370	375	380
Pro Pro Ile Val Ala Arg Tyr Val Arg Val Val Pro Gln Thr Trp His		
385	390	395
Gln Arg Ile Ala Leu Lys Val Glu Leu Ile Gly Cys Gln Ile Thr Gln		
405	410	415
Gly Asn Asp Ser Leu Val Trp Arg Lys Thr Ser Gln Ser Thr Ser Val		
420	425	430
Ser Thr Lys Lys Glu Asp Glu Thr Ile Thr Arg Pro Ile Pro Ser Glu		
435	440	445
Glu Thr Ser Thr Gly Ile Asn Ile Thr Thr Val Ala Ile Pro Leu Val		
450	455	460
Leu Leu Val Val Leu Val Phe Ala Gly Met Gly Ile Phe Ala Ala Phe		
465	470	475
Arg Lys Lys Lys Lys Gly Ser Pro Tyr Gly Ser Ala Glu Ala Gln		
485	490	495
Lys Thr Asp Cys Trp Lys Gln Ile Lys Tyr Pro Phe Ala Arg His Gln		
500	505	510
Ser Ala Glu Phe Thr Ile Ser Tyr Asp Asn Glu Lys Glu Met Thr Gln		
515	520	525
Lys Leu Asp Leu Ile Thr Ser Asp Met Ala Gly		
530	535	

<210> 7

<211> 1768

<212> DNA

<213> homo sapiens

<400> 7

ggcggaggag ctgggtgatg gctgtggaca cctagtgact tatcaggata gtggcacaat	60
gacatctaag aatttatcccg ggacctaccc caatcacact gtttgcggaa agacaattac	120
agtaccaaaag gggaaaagac tgattcttag gttggagat ttggatatcg aatcccagac	180
ctgtgcttc tgcatacttcc tcttcaccag ctcttcagat caaatatggc cataactgtgg	240
aagtatgact gttcccaaag aactcttggt gaacacaagt gaagtaaccg tccgctttga	300
gagtggatcc cacatttctg gccccgggtt tttgctgacc tatgcgagca gcgaccatcc	360
agattnaata acatgtttgg aacgagctag ccatttttg aagacagaat acagcaaatt	420
ctgcccagct ggttgttagag acgttagcagg agacatttc ggaatattgg tagatggata	480
tagagatacc tctttattgt gcaaagctqc catccatgc ggaataattt ctgatgaact	540
aggtggccag atcaagtgtc ttcagcgcaa agggatcagt cgatatgaag ggattctggc	600
caatgggtt ctttcgaggg atgggtccct gtcagacaag cgatttctgt ttacctccaa	660
tggttgcagc agatccctga gttttaaacc tgacggcaa atcagagctt cttcctcatg	720
gcagtcggtc aatgagagtg gagaccaagt tcactggctc cctggccaag cccgacttca	780
ggaccaagc cccatcatggg cttcggggcga cagtagcaac aaccacaaaac caccgagatg	840
gctggagatc gattggggg agaaaaaaagaa aataacagga attaggacca caggatctac	900
acagtcgaac ttcaactttt atgttaaagag ttttggatg aacttcaaaa acaataattc	960
taagtggaaag acctataaaag gaatttgtgaa taatggaaa aaggtgtttc agggtaactc	1020
taactttcgg gaccaggatgc aaaacaattt catccctccc atcgtggcca gatatgtgcg	1080
ggtgtcccc cagacatggc accagaggat agccttgaag gtggagctca ttgggttgc	1140

gattacacaa	ggtaatgatt	cattggtgtg	gcgcaagaca	agtcaaagca	ccagtgttc	1200
aactaagaaa	gaagatgaga	caatcacaag	gcccatcccc	tcggaagaaa	catccacagg	1260
aataaacatt	acaacggtgg	ctattccatt	ggtgctcctt	gttgcctgg	tgttgctgg	1320
aatggggatc	tttcagcct	ttagaaagaa	gaagaagaaa	ggaagtccgt	atggatcagc	1380
ggaggcctcg	aaaacagact	gttggaaagca	gattaaatat	cccttgcca	gacatcagtc	1440
agctgagttt	accatcagct	atgataatga	gaaggagatg	acacaaaagt	tagatctcat	1500
cacaagtgtat	atggcagggtt	aactccgtt	actgccaaaa	tagcatcccc	aacgtgcagc	1560
cctccgcata	tatcagcagg	ttggcccgga	tggatctcag	agatgaggat	tggAACACCA	1620
tgttcttcc	caccctaaca	acaacaaagg	gcagtaaattt	aaagtactct	ttgttaaggtt	1680
cagttaccga	ttaatctaga	gataaaatat	tttcttaaaa	atataatttca	ttaaacacct	1740
atgctgtctc	tatgcaaaaaa	aaaaaaaaaa				1768

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 00/28798

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12N15/12 C07K14/47		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12N C07K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, BIOSIS		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EMBL/GENBANK/DDBJ 'Online! EBI; 16 February 1997 (1997-02-16) "Human DNA sequence from PAC 94G16 on chromosome 6q21" XP002159160 Acc. No. HS94G16	1,3
X	WO 98 45435 A (GENETICS INST) 15 October 1998 (1998-10-15) SEQ ID NO:1452	1,3
A	WO 99 37757 A (INST NAT SANTE RECH MED ;VERROUST PIERRE J (FR); HAMMOND TIMOTHY G) 29 July 1999 (1999-07-29) page 12, paragraph 3 page 58, paragraph 2	1-5
<input type="checkbox"/> Further documents are listed in the continuation of box C.		<input checked="" type="checkbox"/> Patent family members are listed in annex.
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed		
T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *V* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
1 February 2001		13/02/2001
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Mata Vicente, T.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/28798

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9845435 A	15-10-1998	AU EP	6956698 A 0973898 A	30-10-1998 26-01-2000
WO 9937757 A	29-07-1999	AU EP	2462399 A 1047773 A	09-08-1999 02-11-2000